Artis Launches Boston DNA Hub to Fortify US Gene Therapy Supply Chain

BOSTON, MA – March 24, 2026 – In a significant move to strengthen the U.S. infrastructure for next-generation medicines, Artis BioSolutions today announced the establishment of a major synthetic DNA manufacturing hub in Boston. The new facility will leverage the cutting-edge enzymatic DNA synthesis platform from its subsidiary, Syngoi Technologies, creating an integrated, end-to-end solution for gene therapy developers on American soil.

This expansion addresses growing concerns about the fragility of global biopharmaceutical supply chains while simultaneously providing drug developers with faster, higher-purity genetic materials. By integrating this critical manufacturing step into its existing advanced therapy development and GMP manufacturing operations in Watertown, MA, Artis is positioning itself as a key enabler in the rapidly expanding field of genetic medicine, a market projected to exceed $14.9 billion by 2030.

Bolstering the U.S. Biotech Supply Chain

The decision to establish a U.S.-based production hub is a direct response to the vulnerabilities exposed in recent years. The COVID-19 pandemic and ongoing geopolitical tensions have highlighted the risks of relying on single-region sourcing for critical biological components. The advanced therapies industry, with its complex and time-sensitive logistics, is particularly susceptible to such disruptions, which can cause costly delays in clinical trials and patient treatments.

Artis is tackling this challenge head-on by implementing a dual-sourcing strategy, with production capabilities now operating in both the United States and Europe. This approach is designed to ensure service continuity, shorten lead times for North American partners, and reduce logistical hurdles. It also mitigates the operational and geopolitical risks that have become a top concern for biotech executives and investors.

“Artis was founded to more effectively provide platforms and capabilities that drug developers require to bring next-generation medicines to patients,” said Brian Neel, CEO of Artis, in a statement. “Establishing U.S.-based synthetic DNA manufacturing is a pivotal step in the evolution of the Artis platform and reinforces our mission to integrate specialized technologies — from synthetic DNA through GMP manufacturing — into a seamless, end-to-end offering.”

This strategic onshoring aligns with a broader industry trend toward regionalizing manufacturing to build a more resilient and secure supply chain. For a sector where North America represents over 46% of the global market, having domestic production of a fundamental input like synthetic DNA is a crucial step toward self-sufficiency and operational stability.

A Technological Leap in DNA Synthesis

At the heart of the new Boston hub is Syngoi Technologies' proprietary enzymatic platform. This technology represents a paradigm shift away from traditional methods of producing DNA for clinical use, which typically rely on plasmid-based bacterial fermentation. That older process, while established, is often slow, cumbersome, and can introduce impurities that must be painstakingly removed.

In contrast, Syngoi’s enzymatic approach is a cell-free cGMP process that offers significant advantages. It enables the rapid production of highly pure, clinical-grade synthetic DNA with dramatically reduced lead times. This speed and purity are critical for companies working on accelerated development timelines for novel gene therapies and vaccines.

“From our beginning, Syngoi set out to reimagine how clinical-grade synthetic DNA is produced and delivered for advanced therapy applications,” noted Julen Oyarzabal, CSO of Syngoi. The platform's flexibility is another key differentiator. By utilizing a proprietary library of adaptors, Syngoi can manufacture custom DNA constructs optimized for each client's specific therapeutic program.

José Vicente Pons Andreu, CEO of Syngoi, emphasized the strategic advantage of the new location. “Operating in the premier biotechnology innovation ecosystem of the greater Boston area, allows us to respond more rapidly to regional customer demand while maintaining the continuity and technical excellence of our European operations,” he stated. This technological advancement provides the tools necessary to meet the increasing demand for GMP-grade DNA, the largest and fastest-growing segment of the synthetic biology market.

Cementing Boston's Role as a Global Biotech Hub

The choice of the greater Boston area for this facility is no accident. The region is widely regarded as the world's leading biotechnology cluster, boasting an unparalleled concentration of top-tier research institutions, innovative startups, and established pharmaceutical giants. Artis’s move deepens its roots in this vibrant ecosystem, which it first entered with its 2025 acquisition of Landmark Bio.

Landmark Bio, located in Watertown, was itself a product of the region's collaborative spirit, founded in 2021 by a consortium including Harvard University, MIT, FUJIFILM Diosynth Biotechnologies, and Cytiva, with support from leading research hospitals. By acquiring Landmark and now integrating Syngoi's technology into its 44,000-square-foot facility, Artis has created a powerful, localized platform that combines process development, advanced analytics, and GMP manufacturing for both synthetic DNA and advanced therapies.

This integration places Artis in immediate proximity to a dense network of key clients and strategic partners. It allows for closer collaboration and a more agile response to the needs of researchers and clinicians developing groundbreaking treatments. Furthermore, it plugs Artis directly into one of the deepest talent pools for life sciences in the world, ensuring access to the specialized expertise required to operate such an advanced facility.

This investment not only strengthens Artis's commercial offering but also reinforces Massachusetts's standing as a global leader in biomanufacturing. The presence of end-to-end manufacturing capabilities, from foundational genetic material to finished therapeutic products, further solidifies the region's critical role in the future of medicine.

Backed by funding from venture capital firm Oak HC/FT and a reported $250 million in capital deployed across its facilities, Artis is making a well-financed and strategic play. The establishment of the Boston hub is more than just a new building; it is the physical manifestation of a strategy to de-risk and accelerate the entire genetic medicine development pipeline. By combining advanced technology, strategic infrastructure, and a resilient supply chain model, Artis is building a platform designed to empower innovators and, ultimately, deliver next-generation therapies to patients faster.